Page 827 - Basic _ Clinical Pharmacology ( PDFDrive )

CHAPTER 43 Beta-Lactam & Other Cell Wall- & Membrane-Active Antibiotics 813

PREP AR A TIONS A V AIL ABLE

GENERIC NAME AVAILABLE AS GENERIC NAME AVAILABLE AS
PENICILLINS Broad-spectrum (third- & fourth-generation) cephalosporins
Amoxicillin Generic, Amoxil, others Cefdinir Generic
Amoxicillin/potassium Generic, Augmentin Cefditoren pivoxil Spectracef
clavulanate * Cefepime Generic, Maxipime
Ampicillin Generic Cefixime Suprax
Ampicillin/sulbactam sodium † Generic, Unasyn Cefotaxime Generic, Claforan
Dicloxacillin Generic, Dynapen Cefpodoxime proxetil Generic
Nafcillin Generic, Nallpen Ceftaroline fosamil Teflaro
Oxacillin Generic, Bactocill Ceftazidime Generic, Fortaz, Tazicef
Penicillin G Generic, Pfizerpen Ceftazidime/avibactam § Avycaz
Penicillin G benzathine Permapen, Bicillin L-A Ceftibuten Generic, Cedax
Penicillin G procaine Generic Ceftolozane/tazobactam || Zerbaxa
Penicillin V Generic, V-Cillin, Pen-Vee K, Ceftriaxone Generic, Rocephin
others Monobactam & Carbapenems
Piperacillin and tazobactam Zosyn Aztreonam Generic, Azactam, Cayston
sodium ‡ Doripenem Doribax
CEPHALOSPORINS & OTHER BETA-LACTAM DRUGS Ertapenem Invanz
Narrow-spectrum (first-generation) cephalosporins Imipenem/cilastatin Generic, Primaxin IM, Primaxin IV
Cefadroxil Generic Meropenem Generic, Merrem IV
Cefazolin Generic, Ancef, Kefzol OTHER DRUGS DISCUSSED IN THIS CHAPTER
Cephalexin Generic, Keflex, others Cycloserine Generic
Intermediate-spectrum (second-generation) cephalosporins Dalbavancin Dalvance
Cefaclor Generic Daptomycin Cubicin
Cefotetan Generic, Cefotan Fosfomycin Monurol
Cefoxitin Generic Oritavancin Orbactiv
Cefprozil Generic Telavancin Vibativ
Cefuroxime Generic, Ceftin, Zinacef Vancomycin Generic, Vancocin
*
Clavulanate content varies with the formulation; see package insert.
† Sulbactam content is half the ampicillin content.
‡
Tazobactam content is 12.5% of the piperacillin content.
§ Avibactam content is 25% of the ceftazidime content.
||
Tazobactam content is half the ceftolozane content.

REFERENCES Corey GR et al: Single-dose oritavancin versus 7-10 days of vancomycin in the

Biek D et al: Ceftaroline fosamil: A novel broad-spectrum cephalosporin with treatment of gram-positive acute bacterial skin and skin structure infections:
The SOLO II noninferiority study. Clin Infect Dis 2015;60:254.
expanded Gram-positive activity. J Antimicrob Chemother 2010;65(Suppl DePestel DD et al: Cephalosporin use in treatment of patients with penicillin aller-
4):iv9. gies. J Am Pharm Assoc 2008;48:530.
Billeter M et al: Dalbavancin: A novel once-weekly lipoglycopeptide antibiotic. Fowler VG et al: Daptomycin versus standard therapy for bacteremia and endocar-
Clin Infect Dis 2008;46:577. ditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653.
Boucher HW et al: Once-weekly dalbavancin versus daily conventional therapy for Jacoby GA, Munoz-Price LS: The new beta-lactamases. N Engl J Med
skin infection. N Engl J Med 2014;370:2169. 2005;352:380.
Carpenter CF, Chambers HF: Daptomycin: Another novel agent for treating Keating GM, Perry CM: Ertapenem: A review of its use in the treatment of bacte-
infections due to drug-resistant gram-positive pathogens. Clin Infect Dis rial infections. Drugs 2005;65:2151.
2004;38:994.
Centers for Disease Control and Prevention (CDC): Antibiotic resistance threats Kerneis S et al: Cefoxitin as a carbapenem-sparing antibiotic for infections caused
by extended-spectrum beta-lactamase producing Escherichia coli and Klebsi-
in the United States, 2013. Available at: www.cdc.gov/drugresistance/ ella pneumoniae. Infect Dis 2015;47:789.
threat-report-2013/.
Chang C et al: Overview of penicillin allergy. Clinic Rev Allerg Immunol Lee SH et al: TarO-specific inhibitors of wall teichoic acid biosynthesis restore
β-lactam efficacy against methicillin-resistant staphylococci. Sci Transl Med
2012;43:84. 2016;8:329.
Chovel-Sella A et al: The incidence of rash after amoxicillin treatment in children
with infectious mononucleosis. Pediatrics 2013;131:1424.